Briefing
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
ctDNA was studied for clinical significance in high-risk early HER2-negative breast cancer treated with neoadjuvant chemotherapy. The abstract does not name a commercial assay.
- Design: Evidence level 2
- Assay: Not named in the abstract